The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered something of an underdog, with its stock priced accordingly, it's also trading at ...

Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock ...

Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...